(AOF) – Amgen announces that it has signed a one million euro research agreement with Gustave Roussy in order to precisely study the interactions of ADCs (conjugated antibodies), which couple chemotherapy molecules to an antibody, with the tumor cell . The objective is to identify biomarkers to better target the patients on whom these treatments will be effective, and to refine the optimal doses of use. With a budget of one million euros over two years, the research will notably explore the 3 stages following the attachment of the ADC to the tumor cell.
“Amgen was one of the pioneers in the research and development of monoclonal antibodies and is now investing in the development of ADCs. To better understand the elements that come into play in the effectiveness of these therapies, we are happy to begin this ambitious research project in France with Gustave Roussy”, underlines Nathalie Varoqueaux, Medical Director of Amgen France.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.